Follow
Olga Bruyaka
Title
Cited by
Cited by
Year
Do science and money go together? The case of the French biotech industry
R Durand, O Bruyaka, V Mangematin
Strategic Management Journal 29 (12), 1281-1299, 2008
1252008
Run away or stick together? The impact of organization-specific adverse events on alliance partner defection
O Bruyaka, D Philippe, X Castañer
Academy of Management Review 43 (3), 445-469, 2018
862018
Flow signals: Evidence from patent and alliance portfolios in the US biopharmaceutical industry
T Caner, O Bruyaka, JE Prescott
Journal of Management Studies 55 (2), 232-264, 2018
712018
Strategic corporate social responsibility and orphan drug development: Insights from the US and the EU biopharmaceutical industry
O Bruyaka, HK Zeitzmann, I Chalamon, RE Wokutch, P Thakur
Journal of Business Ethics 117, 45-65, 2013
652013
Sell-off or shut-down? Alliance portfolio diversity and two types of high tech firms’ exit
O Bruyaka, R Durand
Strategic Organization 10 (1), 7-30, 2012
622012
Better at home, abroad, or both? How Chinese firms use ambidextrous internationalization strategies to drive innovation
C Prange, O Bruyaka
Cross Cultural & Strategic Management 23 (2), 2016
442016
Investigating the transformation and transition processes between dynamic capabilities: evidence from DHL
C Prange, O Bruyaka, K Marmenout
Organization Studies 39 (11), 1547-1573, 2018
412018
Impact of HIPAA provisions on the stock market value of healthcare institutions, and information security and other information technology firms
L Khansa, DF Cook, T James, O Bruyaka
Computers & Security 31 (6), 750-770, 2012
372012
Antecedents and relative performance of sourcing choices for new product development projects
P Thakur-Wernz, O Bruyaka, F Contractor
Technovation 90, 102097, 2020
302020
Strategic network orchestration in emerging markets: China's catch‐up in the high‐speed train industry
H Rui, O Bruyaka
British journal of management 32 (1), 97-123, 2021
262021
International cultural ambidexterity: balancing tensions of foreign market entry into distant and proximate cultures
O Bruyaka, C Prange
Journal of Business Research 118, 491-506, 2020
222020
Co-evolutionary perspective on sourcing portfolios: Examining sourcing choices for clinical trials of bio-pharmaceutical firms
P Thakur-Wernz, O Bruyaka
Management International Review 57, 909-946, 2017
192017
Using network-based text analysis to analyze trends in Microsoft's security innovations
TL James, L Khansa, DF Cook, O Bruyaka, KB Keeling
computers & security 36, 49-67, 2013
162013
ALLIANCE PARTNER DIVERSITY AND BIOTECH FIRMS'EXIT: DIFFERING EFFECTS ON DISSOLUION VS. DIVESTMENT.
OP BRUYAKA
Academy of management proceedings 2008 (1), 1-6, 2008
122008
Reexamining CEO duality: The surprisingly problematic issues of conceptualization and measurement
S Gove, M Junkunc, O Bruyaka, LR Kabbach de Castro, ...
Corporate Governance: An International Review 25 (6), 411-427, 2017
102017
Big problems require large collective actions: Managing multilateral coopetition in strategic innovation networks
A Rouyre, AS Fernandez, O Bruyaka
Technovation 132, 102968, 2024
72024
Sourcing portfolio diversity in new product development: Antecedents and performance implications
P Thakur-Wernz, O Bruyaka, F Contractor
Journal of Business Research 150, 179-193, 2022
72022
Strategic complementarities in M&As: evidence from the US information retrieval services industry
O Bruyaka, T James, DF Cook, R Barkhi
Information Technology and Management 16, 97-116, 2015
62015
Performance de la RD: Le cas des biotechnologies françaises 1
O Bruyaka
Revue française de gestion, 23-36, 2005
52005
Overcoming innovation barriers: Alliance portfolio characteristics and technological innovations
MK Srivastava, O Bruyaka, DR Gnyawali
32013
The system can't perform the operation now. Try again later.
Articles 1–20